Better Performance
through Insilico Cells™
Company Overview
Insilico Biotechnology is a global
leader in the fields of computational
modelling and simulation of living
cells. Our interdisciplinary team of
experts develops customised solutions
for (i) the efficient manufacturing
of biotechnological products and
(ii) the testing of drugs at preclinical
stages of development. Thanks to a
combination of Insilico’s proprietary
software with high-performance
computing, our customers benefit
from a unique technology platform
backed up by inter­nationally renowned
expertise. Our customers include
leading manufacturing companies such
as BASF, Boehringer Ingelheim, DSM,
Evonik Industries and Wacker. Success-
ful in business since 2001, Insilico’s
interdisciplinary team of biologists,
chemists, computer scientists and
bioprocess engineers is headquartered
in Stuttgart, Germany.
Application Areas & Services
Our experts build predictive, genome-
based metabolic network models
of your organism of interest (Insilico
Cells™). Utilising advanced super-
computing facilities, we carry out
simulations of temporal intra- and
extracellular concentration gradients
through which e. g. effects of media
modifications on cells or toxic effects
of drugs on cells and organs can
be predicted. Apart from metabolic
networks, also gene regulation and
signal transduction networks can be
consulted for these predictions.
In the field of Biotechnological Pro-
cess Optimisation, Insilico helps its
customers to enhance product titres
and productivity through
 Cell line engineering
 Design of optimised media and
feeding strategies
 Development of strategies for clone
selection and upscaling
In the field of Pharmaceutical Test-
ing, Insilico supports your decision
process through
 Quantification and evaluation of
drug effects at cellular scale
 Stratified prediction of local and
systemic drug effects
Products
Our repository of Insilico Cells™
includes network models of
­p rokaryotic organisms such as e. g.
 Escherichia coli
 Bacillus subtilis
 Corynebacterium glutamicum
 Lactobacillus plantarum
as well as compartmented
network models of eukaryotic
­organisms such as e. g.
 Saccharomyces cerevisiae
 Cricetulus griseus (CHO)
 Mus musculus
 Homo sapiens
Your Advantages
According to your specifications, We offer our proprietary technology
Insilico Cells™ can either be adapted platform and expertise on a royalty-
or reconstructed de novo on the basis free fee-for-service basis.
of Insilico’s databases. These data-
bases contain over 2,000 compounds Benefits for our customers include
and over 8,000 biochemical reactions
from more than 60 different organisms,  Improvement of product yield and
and they are steadily expanded. productivity in biotechnological
production processes
The enterprise software Insilico  Preclinical assessment of efficacy
­Discovery™ is a unique modelling and safety of drug candidates
and simulation application developed  Decreased experimental efforts
in collaboration with renowned indus-  Reduced development costs
trial and academic research partners.  Reduced time to market
With Insilico Discovery™, it is easy to  Gain of novel know-how and IP
simulate complex cellular networks
and make predictions answering
the user’s questions. Its seamless
interoperability with Europe’s fastest
computer clusters allows to test
millions of different cellular scenarios
expeditiously by means of petaflop
computing.
Insilico Biotechnology AG

Meitnerstrasse 8
70563 Stuttgart | Germany

Phone + 49 -(0)711- 4 60594-0

Fax + 49 -(0)711- 4 60594-10

info@insilico-biotechnology.com
www.insilico-biotechnology.com